- Home
- DXCM vs ARES Comparison
DXCM vs ARES Comparison
Compare DXCM & ARES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXCM | ARES |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 38.4B |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DXCM | ARES |
|---|---|---|
| Price | $70.27 | $167.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 13 |
| Target Price | $86.41 | ★ $190.67 |
| AVG Volume (30 Days) | ★ 4.8M | 1.8M |
| Earning Date | 02-12-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 2.64% |
| EPS Growth | 7.75 | ★ 9.11 |
| EPS | 1.80 | ★ 2.38 |
| Revenue | $4,515,900,000.00 | ★ $5,355,558,000.00 |
| Revenue This Year | $17.41 | $20.32 |
| Revenue Next Year | $12.73 | $20.88 |
| P/E Ratio | ★ $38.70 | $71.18 |
| Revenue Growth | 14.21 | ★ 45.54 |
| 52 Week Low | $54.11 | $110.63 |
| 52 Week High | $93.25 | $200.49 |
Technical Indicators
Market Signals| Indicator | DXCM | ARES |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 49.45 |
| Support Level | $65.60 | $166.43 |
| Resistance Level | $71.28 | $173.31 |
| Average True Range (ATR) | 2.33 | 4.84 |
| MACD | 0.04 | -0.72 |
| Stochastic Oscillator | 67.72 | 42.62 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About ARES Ares Management Corporation
Ares Management is one of the world's largest alternative-asset managers, with $595.7 billion in total assets under management, or AUM, including $367.6 billion in fee-earning AUM, at the end of September 2025. The company has four main business segments: private credit ($391.5 billion in total AUM and $240.2 billion in fee-earning AUM), private equity, ($25.1 billion/$11.8 billion), real estate/real assets ($132.4 billion/$80.5 billion), and other alternatives ($46.7 billion/$35.1 billion). The firm primarily serves institutional investors (80% of AUM) and high-net-worth individuals (20%). Ares operates through more than 35 offices in over 15 countries around the globe.